Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

“…Similarly, the STREAM and RTOG 3506 trials are currently evaluating enzalutamide in the salvage radiation setting in conjunction with ADT (26,32). Most recently, Attard et al in the phase III STAMPEDE trial show convincing evidence that addition of abiraterone with or without enzalutamide leads to improvement in metastasis-free and overall survival compared to ADT alone in high-risk PCa; although the addition of enzalutamide to abiraterone and ADT did not appear to provide additional treatment effect, the authors add the caveat that the study design could not exclude benefit of enzalutamide (33). In this single arm, single site, phase II clinical trial, we demonstrate that combining non-steroidal AR antagonist enzalutamide and leuprolide in patients undergoing definitive radiation therapy is reasonably well-tolerated and effective.…”

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review

“…In the same population, the ARASENS trial has demonstrated the benefit of adding darolutamide to ADT plus docetaxel. In high-risk localized disease the STAMEDE trial has demonstrated the benefit of two years of abiraterone in addition to ADT and radiotherapy to the primary tumor [ 40 ]. Overall, these data suggest that treatment intensification, as opposed to treatment waiting, can provide significant benefit for patients with both hormone-sensitive and castration-resistant disease.…”

Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy

“…This is a significant finding in view of the unpleasant side effects of ADT and its adverse impact on quality of life. A phase III trial (Stampede) has shown that ADT combined with an androgen synthesis blocking drug (abiraterone acetate plus prednisolone) provides improved benefits over ADT alone against non-metastatic castration sensitive PCa [ 13 ]. Therapeutic ADT includes agonists or antagonists for luteinizing hormone-releasing hormone (LHRH).…”

“…ADT paired with abiraterone-prednisone is approved for metastatic castration-resistant prostate cancer (mCRPC). A phase III trial (STAMPEDE) on non-metastatic castration-sensitive prostate cancer has shown superior patient outcomes with ADT plus abiraterone acetate/prednisone compared to stand-alone ADT [ 13 ]. In a phase III trial (PEACE-1) targeting patients with de novo metastatic castration-sensitive prostate cancer, adding abiraterone/prednisone to ADT and docetaxel (a chemotherapeutic) improved radiographic progression-free survival [ 24 ].…”